Introduction
Correct initiation of transcription of protein-encoding genes by RNA polymerase II (Pol II) requires the transcription factor TFIID, which is comprised of TATA-binding protein (TBP) and a number of TBP-associated factors (TAF II s) (Tansey and Herr, 1997) . The exact role of TAF II s in transcription initiation is unknown. Initial in vitro transcription studies suggested that TAF II s may work as general co-activators to mediate the transcriptional activation of the different activators (Goodrich et al., 1996) . It was also shown that recombinant TBP can substitute in vitro for TFIID in reconstituted transcription systems, but does not support transcription from TATAless promoters (Pugh and Tjian, 1991; Zhou et al., 1992) .
Evidence that TAF II s function as co-activators in mammalian cells has been provided by studies showing that hTAF II 28 and hTAF II 135 enhance transcriptional activation by nuclear receptors (May et al., 1996; Mengus et al., 1997) . Further evidence that TAF II s are required for transcriptional activation came from genetic studies of D.melanogaster which showed that mutations in dTAF II s lead to specific defects in transcriptional activation in the embryo (Zhou et al., 1998) .
In yeast (y) strains lacking functional yTAF II s, a variety of inducible genes are normally transcribed in vivo Moqtaderi et al., 1996a; Walker et al., 1996) . Nevertheless, TAF II s do play an essential role in yeast, as mutant strains are not viable (Moqtaderi et al., 1996b) . Thus, TAF II s may not generally be required for activatordependent transcription, but seem to be essential for the transcription of certain genes.
Functionally distinct TFIID populations, sharing common TAF II s but differing in their specific TAF II composition, have been isolated from mammalian cells (Bell and Tora, 1999) . TFIID complexes that either contain (TFIIDβ) or lack (TFIIDα) hTAF II 30 have been separated from mammalian cells extracts (Jacq et al., 1994; Mengus et al., 1995) . Human TAF II 30 is present in only~50% of TFIID complexes and is therefore considered a 'specific' TAF II (Jacq et al., 1994) . Recently, a novel multiprotein complex containing neither TBP nor TBP-like factor (TLF), but comprising hTAF II 30 and several other TAF II s, has been characterized (Wieczorek et al., 1998) . This complex, called TBP-free TAF II -containing complex (TFTC), can replace TFIID in in vitro transcription assays (Wieczorek et al., 1998) and contains histone acetyl transferase (HAT) activity (Brand et al., 1999) . Moreover, TAF II 30 and its yeast homologue yTAF II 25 are present in several other TAF II -HAT-containing complexes, the yeast SAGA and the human PCAF/GCN5 complexes (Grant et al., 1998; Ogryzko et al., 1998) .
To understand the functions of mammalian TAF II s in the regulation of Pol II transcription in vivo, and more specifically that of TAF II 30, we have inactivated both alleles of the TAF II 30 gene in murine embryonal carcinoma F9 cells. The F9 cell line provides an interesting model system to analyse the role of a given transcription factor during either cell proliferation and/or cell differentiation. Treatment of F9 cells with all-trans retinoic acid (RA) induces primitive endodermal differentiation (Strickland and Mahdavi, 1978) , whereas treatment with RA and dibutyryl c-AMP (bt 2 cAMP) induces a parietal endodermal phenotype (Strickland et al., 1980) . Moreover, the RAinduced differentiation of F9 cells is accompanied by a dramatic decrease in the proliferation rate, an increase in the fraction of cells arrested in G 1 /G 0 phase of the cell cycle and an increase in the number of apoptotic cells (Clifford et al., 1996 , and references therein). The RAinduced differentiation is mediated by the RA receptors (RARs) and the retinoic X receptors (RXRs) (Chiba et al., 1997a , and references therein). The two TAF II 30 alleles have been targeted here by homologous recombination (HR) and subsequently disrupted by using a Cre recombinase-loxP strategy (Sauer and Henderson, 1990 
Results

Conditional targeting of the TAF II 30 gene in F9 cells
To inactivate the TAF II 30 gene by HR, we first cloned and characterized the mouse gene (Figure 1 ). The structure of the mouse (m) TAF II 30 gene is very similar to the human TAF II 30 gene (TAF2H; Scheer et al., 1995) , i.e. it consists of five exons (Figure 1 ). The mTAF II 30 coding sequence deduced from the genomic sequence is 759 bases long (89% identical to the human cDNA) and encodes a 218 amino acid protein that is 90.3% identical to the human TAF II 30 protein.
To perform a conditional disruption of the mTAF II 30 gene in F9 cells, we used a Cre-loxP strategy, similar to that previously described (Sumi-Ichinose et al., 1997) . We constructed two targeting vectors (Figure 1B and C) , in which a loxP site (hereafter termed L) was inserted into the intron located upstream of exon 2, while a neomycinresistance gene expression cassette (tk-neo, hereafter termed N) flanked by two loxP sites ('floxed') was inserted into the intron located downstream of exon 2. Thus, following targeting of the wild-type (WT) alleles by HR, the Cre recombinase will allow the excision of exon 2 as well as the floxed selection marker cassette, resulting in the deletion of the sequences encoding amino acid residues 78 (alanine) to 130 (isoleucine) and the creation of a frame shift in the beginning of exon 3 with a stop codon (Figure 1 and data not shown). Thus, the putative truncated protein produced from the disrupted gene will lack the evolutionary highly conserved C-terminal domain of TAF II 30.
To target the first allele of the TAF II 30 gene, F9 cells were electroporated with the pTAF II 30 (L:LNL)a vector ( Figure 1B Figure 2A and C). Cells from one of the TAF II 30 (L:L)a/ϩ clones were then electroporated with the second targeting vector ( Figure 1C ) and cells containing the second targeted TAF II 30 allele were identified (Figures 1, 2B and C) . Note that in the second targeting vector, the three loxP sites were in the opposite orientation when compared with the previously used vector.
To excise the sequences located between the loxP sites, the TAF II 30 (L:L)a/(L:LNL)b cells ( Figure 2B) Figure 2B ). Amongst these clones, all the possible different genotypes for the two TAF II 30 alleles were present ( Figure 2B and C and data not shown). Thus, it appears that either one of the two alleles of the mouse TAF II 30 gene can be independently inactivated, but that inactivation of both TAF II 30 alleles may be lethal. Figure 3B ). The intensity of the 706 bp signal corresponding to the (L:L)b allele was similar in all the samples analysed. In contrast, although the 233 bp signal corresponding to theLb allele could be detected 1 day after Cre recombinase electroporation, it decreased at day four, and finally disappeared totally between days five and seven ( Figure 3B and data not shown). Thus, F9 cells with both TAF II 30 alleles inactivated were obtained, but were apparently severely affected in their proliferation and could not be cloned.
Inactivation of both TAF
Conditional rescue of TAF II 30 -La/-Lb cells with human TAF II 30
To demonstrate unequivocally that the failure to obtain an F9 cell line in which both mTAF II 30 alleles are inactivated, was due to an absolute requirement of the TAF II 30 protein for cell proliferation, and to allow further studies of TAF II 30 function, we generated a Dox-inducible TAF II 30 expression system. We stably integrated an expression cassette encoding the reverse tetracycline-controlled transactivator (rtTA; Gossen et al., 1995) (Jacq et al., 1994) Figure 3D ). Inter- estingly, in the TAF II 30 -La/-Lb :R cells neither a truncated mTAF II 30 mRNA nor a truncated protein could be detected by Northern and Western blotting analyses, respectively ( Figure 3D ). Therefore, the -La and -Lb alleles are true null alleles.
To investigate the role of TAF II 30 in cell proliferation, we cultured the TAF II 30 -La/-Lb :R cells in the absence and presence of Dox. One day after Dox withdrawal, the hTAF II 30 protein level decreased by~50% and became undetectable from the second day after Dox withdrawal ( Figure 4A ), whereas in the presence of Dox the hTAF II 30 levels were constant over several weeks ( Figure 4A and data not shown). The growth rates of TAF II 30 -La/-Lb :R 4825 cells grown either in the presence or absence of Dox were similar for the first 2 days, but in the absence of Dox the cells became arrested after 3 days, and almost all the cells were dead after 6 days. Whereas cells grew to confluency in the presence of Dox [Figures 4B and 7A (b) and (c) Figure 4A and data not shown). 
TAF II 30 is required for G 1 -S phase cell cycle progression
The cell cycle profile of the TAF II 30 -La/-Lb :R cells grown in the absence or presence of Dox was investigated by flow cytometry. In agreement with the proliferation rate studies ( Figure 4B ), no significant differences in the cell cycle profiles were seen between TAF II 30 -La/-Lb :R cells grown for 2 days in the absence or presence of Dox ( Figure 4C ). In contrast, 5 days after Dox withdrawal the TAF II 30-null cells accumulated in G 1 /G 0 phase. The proportion of cells in G 1 /G 0 phase increased from~39 to 61% ( Figure 4C ). We then investigated the mRNA level of different cell cycle-related cyclin genes in TAF II 30-null cells. Reverse transcription-polymerase chain reaction (RT-PCR) analysis was used to obtain a semi-quantitative estimation of the expression of different genes (see Materials and methods). Cyclin E expression was progressively reduced from the third to the fifth day after Dox withdrawal (~6.6-fold reduction at the fifth day), when compared with either the expression in cells grown in the presence of Dox or WT cells ( Figure 5A and B). In contrast, the expression of the other tested cyclins was either not, or was only weakly altered after the suppression of hTAF II 30 synthesis ( Figure 5A and B) . Cyclin E, which is expressed at maximal levels in the G 1 -S transition and interacts with its catalytic partner cdk2, is a key regulator of G 1 progression during the cell cycle (Sherr, 1994; Reed, 1997) . The strong reduction of cyclin E expression in TAF II 30-null cells is in good agreement with the results obtained by flow cytometry indicating that TAF II 30-null cells accumulate in G 1 phase.
Phosphorylation of retinoblastoma protein (pRb) in G 1 inactivates its growth inhibitory function, allowing cell cycle progression (Bartek et al., 1997) . As cyclin Ecdk2 complex collaborates with the D-type cyclin-cdk4/6 complexes for pRb phosphorylation (Hatakeyama et al., 1994; Lundberg and Weinberg, 1998) , we investigated the phosphorylation state of pRb in the TAF II 30-null cells. In WT and TAF II 30 -La/-Lb :R cells expressing hTAF II 30 protein,~70% of pRb was phosphorylated ( Figure 5C , lanes 1 and 2). In contrast, the level of pRb phosphorylation (Jacq et al., 1994) , which is specific for the human protein. The Northern blotting was carried out by standard methods using cytoplasmic RNA isolated from the indicated cell lines and hybridized with a mTAF II 30 cDNA probe. The Western blotting was carried out with protein extracts isolated from the indicated cell lines using the 1H8 anti-TAF II 30 mAb, directed against the N-terminal end of TAF II 30 (Wieczorek et al., 1998) . The arrowheads on the Northern and Western blots indicate the sizes of the putative truncated mTAF II 30 RNA and protein, respectively. decreased after stopping hTAF II 30 expression, and after 5 days of culture in the absence of Dox, pRb was essentially unphosphorylated ( Figure 5C , lane 6). Note that the expression of pRb mRNA was not affected in the TAF II 30-null cells (data not shown). Taken together, the above results show that TAF II 30 is required for G 1 -S phase cell cycle progression and cyclin E expression.
TAF II 30-null F9 cells undergo apoptosis
When the TAF II 30 -La/-Lb :R cells were grown for 5 days in the absence of Dox,~82% of the cells had a sub-2N size DNA content, whereas only~6% of such particles were detected in the presence of Dox, suggesting that most of the TAF II 30-lacking cells die by apoptosis ( Figure 4C ). During apoptosis endonucleases that preferentially cut DNA are activated. The characteristic DNA 'ladder' of fragmented DNA appeared 4 days after growing the TAF II 30 -La/-Lb :R cells in the absence of Dox and its amount increased with time ( Figure 6C, lanes 17, 21 and  25 ). The translocation of the membrane phospholipid phosphatidylserine (PS) from the inner to the outer leaflet of the plasma membrane is another feature of apoptotic cells. Annexin V binds specifically to PS of cells and therefore allows detection of cells early in apoptosis (Philippe et al., 1997) . To distinguish early apoptotic from late apoptotic cells we used annexin V in combination with propidium iodide (PI). The proportion of pre-apoptotic particles was similar when TAF II 30 -La/-Lb :R cells were grown for 2 days in the absence or presence of Dox ( Figure 6A , 4 and 10% annexin Vϩ, PI-cells, respectively). However, 5 days after Dox withdrawal Ͼ60% of the TAF II 30 -La/-Lb :R cells were pre-apoptotic, whereas when the cells were grown in the presence of Dox for 5 days, only 16% were pre-apoptotic ( Figure 6A ). Taken together, these results demonstrate that F9 cells undergo apoptosis in the absence of TAF II 30 expression.
Parietal, but not primitive endodermal differentiation is impaired in TAF II 30-null cells
To analyse the function of TAF II 30 during RA-induced differentiation, TAF II 30 -La/-Lb :R cells were grown for 60 h as monolayers in the presence or absence of Dox, and then grown further in the presence or absence of 1 μM RA. As for WT cells, RA induced a severe decrease of the proliferation rate of TAF II 30 -La/-Lb :R cells expressing hTAF II 30 (ϩDox) ( Figure 6D and data not shown) and induced a primitive endodermal-like morphological Figure 7A (e) and (f)]. Thus, the genes which are required for this differentiation pathway are expressed in the TAF II 30-null cells. Furthermore, several RA-inducible genes, i.e. RARβ2, Hox-1, Stra4 and Stra8 (Chiba et al., 1997b) were similarly induced in TAF II 30-null and WT cells after 2 days of RA treatment (data not shown). Moreover, the RA-treated TAF II 30-null cells survived for Ͼ10 days ( Figure 6D ). Interestingly, in the presence of RA the TAF II 30 -La/-Lb :R cells arrested with a 4829 similar time course when grown in the absence or presence of Dox ( Figure 6D ). The RA treatment of TAF II 30 -La/-Lb :R cells grown in the presence of Dox resulted in a moderate increase (from 16 to 22%) in preapoptotic cells (compare ϩDox 5 days in Figure 6A with B), in agreement with previous studies performed on WT F9 cells (Clifford et al., 1996) . Note that this low level of apoptosis could not be visualized in the DNA ladder assay used in this study ( Figure 6C and data not shown) . In contrast, the RA treatment of the TAF II 30 -La/-Lb :R cells in the absence of Dox resulted in a strong reduction in pre-apoptotic cells (from 61 to 20%) as detected by fluorescence-activated cell sorting (FACS) analysis (compare -Dox 5 days in Figure 6A with B) or by the absence of fragmented apoptotic DNA 'ladder' ( Figure 6C , compare lanes 17 with 18, 21 with 22, and 25 with 26).
To induce parietal endodermal differentiation, WT and TAF II 30 -La/-Lb :R cells were grown in monolayer culture in the absence or presence of Dox and treated with 1 μM RA and 250 μM bt 2 cAMP. The morphological changes which normally accompany RA ϩ cAMP-induced differentiation of WT cells were observed in TAF II 30 -La/-Lb :R cells expressing hTAF II 30 [ Figure 7A (h)]. In contrast, TAF II 30-null cells (-Dox), although they differentiated into primitive endoderm-like cells, were strongly impaired in parietal endodermal differentiation. The parietal differentiation of WT and mutant cells was also investigated by determining the expression of the thrombomodulin (TM) gene, a marker of parietal endodermal differentiation (Niforas et al., 1996 ; C.Rochette-Egly, personal communication). As expected, after 10 days of RAϩcAMP treatment, TM was strongly stimulated in WT and mutant cells expressing hTAF II 30 (ϩDox) (Ͼ90-fold, Figure 7B ). In contrast, in the TAF II 30-null cells (-Dox) the induction of TM was very low (Ͻ6-fold) and the levels of TM were at least five times lower than in the WT or hTAF II 30 expressing (ϩDox) cells ( Figure 7B ). Taken together, these results indicate that TAF II 30-null cells are strongly impaired in parietal, but not primitive endodermal differentiation.
Discussion TAF II 30-null F9 cells are not viable
In this study, we performed conditional disruption of the TAF II 30 gene in F9 murine embryonal carcinoma cells, using a Cre/LoxP strategy. No F9 cell clone disrupted for the two alleles could be isolated, indicating that undifferentiated TAF II 30-null F9 cells are impaired in their proliferation. This was confirmed by a study of the genotype of a TAF II 30 ϩ/-[TAF II 30 -La/(L/L)b ] F9 cell population after Cre-mediated disruption of the second allele. Although TAF II 30 -/-(TAF II 30 -La/-Lb ) cells could be detected during the 5 days which followed Cre recombinase transfection, their number did not increase with time and they eventually disappeared after a week, whereas TAF II 30 ϩ/-cells proliferated normally. The Cre-mediated disruption of the targeted alleles encodes a truncated protein lacking the C-terminal evolutionary conserved domain. Importantly, neither the truncated mRNA nor the protein could be detected in heterozygous cells (TAF II 30 ϩ/-) or in rescue cells in which both alleles are 
TAF II 30 is required for G 1 /S progression of the cell cycle and cyclin E expression
The conditional expression of hTAF II 30 in TAF II 30 -/-cells allowed us to study its role in the cell cycle regulation. FACS analysis showed that TAF II 30-null cells accumulate in G 1 /G 0 phase. Molecular analyses revealed that cyclin E expression is down-regulated after suppression of TAF II 30 expression, while expression of cyclin-dependent kinase inhibitor p21 is enhanced (data not shown). Consistent with the decreased cyclin E and increased p21 expression, we found that phosphorylation of pRb is decreased in TAF II 30 lacking cells. These changes are all possible causes of the G 1 cell cycle arrest phenotype of the TAF II 30 lacking cells. Taken together, these results suggest that TAF II 30 may regulate cyclin E expression and that only certain genes are regulated (directly or indirectly) by TAF II 30.
Interestingly, growth arrest of yTAF II 90 and yTAF II 150 (Tsm1) mutant yeast strains occurs at the G 2 /M boundary of the cell cycle, whereas yTAF II 145 mutant strains arrest in G 1 phase Walker et al., 1996) . yTAF II 145 has been shown to be required for transcription of G 1 cyclins and certain B-type cyclin genes (Walker et al., 1997) . Furthermore, a hamster cell line containing a temperature-sensitive mutation in TAF II 250 undergoes G 1 arrest upon shifting to the restrictive temperature (Sekiguchi et al., 1991) , resulting in reduced transcription of G 1 cyclin genes such as cyclin A and D1 (Wang and Tjian, 1994; Suzuki-Yagawa et al., 1997; Wang et al., 1997) . Thus, different TAF II s may specifically regulate distinct cyclin genes to control cell proliferation.
RA prevents cell death of TAF II 30-null cells and induces primitive, but not parietal endodermal differentiation Our results indicate that cells lacking TAF II 30 are not simply arrested in G 1 /G 0 phase of the cell cycle, but undergo apoptosis ( Figures 4C, 6A and C) . The analysis of the expression of 80 genes (on a mouse cDNA expression array) involved in the regulation of apoptosis, revealed that the mRNA levels of 14 genes were up-regulated (i.e. encoding caspase 3, 6 and 11, BAD and BID) and five genes were down-regulated (encoding i.e. the p55 cell division control protein and the glutathione S-tranferase Mu 1 protein) in TAF II 30-null cells when compared with cells expressing hTAF II 30 (data not shown). Whether TAF II 30 is directly or indirectly involved in the regulation of these genes is unknown. The lack of TAF II 30 may induce apoptosis indirectly by deregulating distinct cell cycle check-points, i.e. pRb and/or E2F activities. A recent study has suggested that another 'specific' TAF II , hTAF II 105, is involved in activation of anti-apoptotic genes by serving as a co-activator for NF-κB, a factor known to protect cells from apoptotic stimuli (Yamit-Hezi and Dikstein, 1998) . It is therefore conceivable that TAF II s may regulate anti-apoptotic events through different pathways.
Interestingly, after RA-treatment, TAF II 30-null cells did not die, but differentiated into primitive endodermal-like cells, and arrested with a similar time course to the RAtreated WT F9 cells ( Figure 6D ). Therefore, in contrast to WT cells (where RA not only induces differentiation, but also antiproliferation and apoptosis), RA-induced differentiation prevents TAF II 30-null cell death by strongly reducing apoptosis. These data suggest that when the cells are programmed to proliferate, a G 1 check-point, where the TAF II 30 function is indispensable, does not function properly and apoptosis is triggered. On the other hand, when cells are programmed to differentiate by RA, the G 1 check-point is not used since the cells enter G 0 , and thus TAF II 30-null cells differentiate into primitive endodermal cells and survive. Strikingly however, the genes that are needed to trigger the morphological changes leading to primitive endodermal differentiation, are correctly expressed in TAF II 30-null cells. In contrast, parietal endodermal differentiation is strongly impaired in TAF II 30-null cells. Parietal endodermal differentiation is apparently achieved in two steps, an initial RA-induced differentiation into primitive endoderm, followed by a cAMP-induced differentiation switch from primitive to parietal endoderm (Strickland et al., 1980 (Moqtaderi et al., 1996a; Walker et al., 1996) , the expression of different mTAF II s and mTBP was not affected in TAF II 30-null cells ( Figure 4B ) further suggesting that the TFIID, TFTC and PCAF/GCN5 complexes may function without TAF II 30.
Our results demonstrate that mammalian TAF II s are not generally required for activator-dependent transcription, but are essential for the transcription of specific genes. Further in vitro experiments will be needed to understand the exact molecular mechanisms by which TAF II 30 in the different TAF II 30-containing complexes, such as TFIID, TFTC and PCAF/GCN5, modulates the transcription of a subset of genes.
Materials and methods
Cloning of the mouse TAF II 30 gene and determination of exon-intron boundaries
A mouse embryonic stem (ES) cell genomic library constructed in λGEM12 phage was screened with a 300 bp human TAF II 30 cDNA probe (from position 355 to 654; Jacq et al., 1994) . A 16 kb DNA fragment containing the entire mouse TAF II 30 gene and its flanking sequences was subcloned in pBluescript II SKϩ (pBSK, Stratagene) and mapped with restriction enzymes (Figure 1) . The exon-intron boundaries of the mouse (m) TAF II 30 gene were determined by DNA sequencing.
Targeting of the TAF II 30 gene in F9 cells
The targeting vectors pTAF II 30 (L:LNL)a and pTAF II 30 (L:LNL)b were constructed as follows. The 3.2 kb BamHI-EcoRI restriction fragment, containing exons 1, 2 and 3 of the mTAF II 30 gene ( Figure 1A ), was subcloned into the corresponding sites of pBEX, resulting in pBEX-TAF1-3. pBEX is a pBSK derived vector containing a new polylinker (BamHI, EcoRI and XhoI), obtained by cloning the oligonucleotides 5Ј-GGTACCGTGGAATTCAGCTCGAGAGTAC-3Ј and 5Ј-TCTCGA-GCTGAATTCCACGGTACCAGCT-3Ј into the SacI and KpnI sites of pBSK. A SalI site was introduced between exons 1 and 2, and a NotI site between exons 2 and 3 by site directed mutagenesis of pBEX-TAF1-3 with the oligonucleotides 5Ј-CCCCGGCACCTAGTCGACG-ATGCCCTCCTCCTCCCT-3Ј and 5Ј-GGCAGAGGCAGGCGGCCGC-TGAGTTCAAAGCCAG-3Ј, respectively, resulting in pBEX-TAFSN. The oligonucleotides 5Ј-TCGACATAACTTCGTATAATGTATGCTA-TACGAAGTTATGGTACC-3Ј and 5Ј-TCGAGGTACCATAACTTCGT-ATAGCATACATTATACGAAGTTATG-3Ј, containing a loxP site (labelled as La or Lb in the following constructions, depending on their orientation), were cloned into the SalI site of pBEX-TAFSN, resulting in pBEX-TAF La N and pBEX-TAF Lb N. To clone the floxed tk-Neo cassette (Metzger et al., 1995) into the NotI site of pBEX-TAF La N and pBEX-TAF Lb N vectors, a polylinker containing the following restriction sites (NotI, ClaI, BglII, XbaI, SacI and NotI; 5Ј-GCGGCCGCTAAATCG-ATTCGAGATCTCAAGTCTAGAGACGAGCTCTAAGCGGCCGCG-TAC-3Ј ) was cloned in the SacI and KpnI sites of pBSK, resulting in pBSK-NBXN. The 3.2 kb BamHI-XbaI fragment containing the floxed tk-Neo cassette, isolated from pHR56 (Metzger et al., 1995) , was cloned into the corresponding sites of pBSK-NBXN, resulting in pN LNL -XN. (Figure 1 ). The Cre expression vector pSG-Cre was obtained by cloning a PCR-amplified Cre gene (Metzger et al., 1995) into the EcoRI-BglII sites of pSG5.
F9 cells were electroporated with 5 μg of the 13.8 kb BamHI-XhoI fragment, isolated either from pTAF II 30 (L:LNL)a or pTAF II 30 (L:LNL)b vectors (Figure 1) , or with 5 μg of the pSG-Cre expression vector (Clifford et al., 1996) . The selection of neomycin-resistant clones, Cre recombinase mediated excision and Southern blot analysis were performed as described (Metzger et al., 1995) . The 5Ј probe corresponds to a 0.8 kb EcoRV-KpnI genomic fragment, located outside the genomic sequences present in the targeting vector ( Figure 1A) . The primers used for the identification of the genotypes (Figures 2C and 3C ) and their locations were as follows: SG12 (5Ј-CTGCCCACTAGCACGGCC-3Ј) located in the first exon, SE89 (5Ј-CAGTCTAACCTGCTCCGAG-3Ј) located between exons 3 and 4, and WY60 (5Ј-CGCTTAGAGCTCGT-CTCTAG-3Ј) specific to the junction between the Loxb site and intron 2 (Figures 1 and 3) . 
cells
The expression vector pDG1-rtTA, in which the expression of the rtTA (Gossen et al., 1995) is under the control of the PGK promoter, was constructed by inserting the 1044-bp EcoRI-BamHI fragment isolated from pUHD172-1Neo (Gossen et al., 1995) into the corresponding sites of the pDG1 expression vector. An EcoRI-BglII human TAF II 30 cDNA fragment was excised from pXJ-TAF30 (Jacq et al., 1994) and cloned into the EcoRI-BamHI sites of the pUHD10-3 vector (Gossen and Bujard, 1992) , resulting in the expression vector pUHD10-TAF30 in which the expression of hTAF II 30 is under the control of the tet-operator. The TAF II 30 -La/( L:L)b F9 cells were co-electroporated with 5 μg of pDG1-rtTA and linearized by AatII and with 0.5 μg of XhoI-digested pPGK-hygro vector (te Riele et al., 1990) . After hygromycin selection, rtTA positive clones were selected by genomic PCR using the primers QY74 (5Ј-CACGCTTCAAAAGCGCACGT-3Ј) and WK31 (5Ј-CAAT-ACAGTGTAGGCTGCTGCTC-3Ј), and by Western blotting analysis using three anti-VP16 monoclonal antibodies (2GV4, 5GV2 and 5GV7; White et al., 1992) . A rtTA positive TAF II 30 -La/( L:L)b cell line was coelectroporated with 5 μg of the 2 kb AatII-HindIII DNA fragment isolated from pUHD10-TAFII30 and with 0.5 μg of the neomycinresistance cassette (a 1.6 kb BglII DNA fragment isolated from the vector pKJ-1B; pKJ-1B was obtained by cloning the oligonucleotide 5Ј-AATTAGATCT-3Ј into the EcoRI site of pKJ1; McBurney et al., 1991) . After neomycin selection, cells were treated with 1 μg/ml Dox for 3 days, and hTAF II 30 positive clones were selected by Western blot analysis using the human TAF II 30-specific antibody 2F4 (Jacq et al., 1994) .
Western blot analysis
Cells resuspended in 20 mM Tris-HCl pH 7.5, 2 mM DTT, 20% glycerol, 0.4 M KCl, 1 mM PMSF and protease inhibitor cocktail (2.5 μg/ml of leupeptin, pepstatin, chymostatin, antipain and aprotinin), were lysed by three cycles of freeze-thaw and cell debris was eliminated by centrifugation. Proteins were loaded on a 10% SDS-polyacrylamide gel, separated by electrophoresis and electroblotted. The blots were then treated with monoclonal antibodies followed by incubation with peroxidaseconjugated goat anti-mouse IgG antibody (Jackson Immuno Research). Chemiluminescence detection was performed according to the manufacturer's instructions (Amersham).
PCR amplification of genomic DNA and RT-PCR
Genomic DNA was prepared as follows: cells grown in 6-well plates were collected in 500 μl of lysis buffer (50 mM Tris-HCl pH 8.0, 200 mM NaCl, 5 mM EDTA, 1% SDS and 0.2 mg/ml proteinase K) and incubated overnight at 55°C. The lysate was extracted with phenol/ chloroform and chloroform and precipitated with ethanol at room temperature. PCR amplifications were performed in 50 μl reactions containing 67 mM Tris-HCl pH 8.8, 16 mM (NH 4 ) 2 SO 4 , 10 mM β-mercaptoethanol, 1.5 mM MgCl 2 , 10% DMSO, 0.2 mM dNTPs, primers (12.5 pmol each), 1 μl of proteinase K-treated cell extract or 20 ng of purified genomic DNA and 2.5 U Taq polymerase. The amplification conditions were: 94°C for 5 min followed by 35 cycles at 94°C for 30 s and 55°C for 30 s, and finally one cycle at 94°C for 30 s, 50°C for 30 s and 72°C for 5 min.
Cytoplasmic RNA extraction following cell lysis with 0.5% NP-40
and semi-quantitative RT-PCRs were performed as described (Chiba et al., 1997b) . The PCR primers used for amplification of the different transcripts are available upon request. To make sure that amplifications were in the linear range, aliquots of PCR products were taken from each reaction at three different cycles between cycles 15 and 25, depending on the gene analysed (Freeman et al., 1994) . Control experiments were performed to determine the range of PCR cycles over which amplification efficiency remained linear and to verify that the amount of PCR product was directly proportional to the amount of input RNA (data not shown). End-labelled oligonucleotides were generated for probing the PCR products on Southern blots. Transcript levels were quantified with a BAS 2000 bio-imaging analyser (Fuji Ltd) and were normalized to the corresponding HPRT levels.
Analysis of F9 cell growth and differentiation
Cells were seeded in 10-cm culture dishes at a density of 10 4 cells/well at day zero, in the presence or absence of 1 μg/ml Dox. The medium was changed every second day, and 1 μM RA or 1 μM RA ϩ 250 μM bt 2 cAMP was added as indicated. Cells were counted with a particle counter (Coulter Z2) and their differentiation status was examined under light microscopy as described (Clifford et al., 1996) .
Flow cytometric quantitation of cell cycle and apoptosis, and extraction of low mol. wt DNA Flow cytometric quantitation of cell cycle was carried out as described in Clifford et al. (1996) , except that instead of ethidium bromide, propidum iodide (PI) was used at a final concentration of 25 μg/ml. Flow cytometric quantitation of apoptosis using annexin V together with PI was as described (Lecoeur and Gougeon, 1996; Philippe et al., 1997) . PI stains non-fixed cells in late-apoptotic and necrotic stages as these cells have lost their membrane inegrity. Briefly, 0.2ϫ10 6 cells were resuspended in 50 μl of AV buffer (10 mM HEPES-NaOH pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl 2 and 1.8 mM CaCl 2 ) and incubated with 1 μl FITC-labelled AV (CALTAG Laboratories) for 30 min at room temperature in the dark. Five hundred microlitres of AV buffer containing 5 μg/ml PI was added for 5 min (in the dark) and the samples were analysed on a FACScan (Beckton Dickinson) equipped with a single argon ion laser. A minimum of 10 000 cells per sample were analysed with the CELLQuest software (Beckton Dickinson). Extraction of low mol. wt DNA from apoptotic cells was done in 0.2 M phosphate-citrate buffer pH 7.8, as described by Gong et al. (1994) .
